Cannabidiol (CBD) reduces anxiety-related behavior in mice via an FMRP-independent mechanism

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• Fragile X Syndrome (FXS) is a genetic neurodevelopmental disorder caused by FMR1 gene mutations.
• Fmr1 knockout (KO) mice serve as a preclinical model for FXS research.
• Investigating non-psychoactive phytocannabinoids like cannabidiol (CBD) for potential FXS therapeutics.

Purpose of the Study:

• To evaluate the behavioral effects of CBD in male Fmr1 KO mice, a model for Fragile X Syndrome.
• To determine if CBD can normalize the abnormal behaviors observed in Fmr1 KO mice.
• To assess CBD's impact on anxiety, locomotion, and cognition in this preclinical model.

Main Methods:

• Administration of vehicle or CBD (5, 20 mg/kg) to adult Fmr1 KO and wild-type (WT) mice.
• Behavioral testing including open field, elevated plus maze, spontaneous alternation, social preference, and passive avoidance.
• Measurement of brain and plasma CBD concentrations to assess pharmacokinetics.

Main Results:

• Fmr1 KO mice exhibited hyperlocomotion, hyperexploration, and slower habituation, with reduced anxiety-like behaviors.
• CBD administration showed subtle effects, primarily reducing anxiety in the elevated plus maze for all tested mice.
• CBD did not impact locomotion or anxiety in the open field, nor did it affect cognitive performance in Fmr1 KO mice.
• Fmr1 KO mice demonstrated faster plasma CBD clearance compared to WT mice.

Conclusions:

• Acute CBD administration at tested doses did not selectively ameliorate behavioral abnormalities in Fmr1 KO mice.
• CBD exhibited anxiolytic effects in both Fmr1 KO and WT mice, indicating a general anxiety-reducing property.
• The findings suggest CBD may not be a targeted therapy for FXS-specific behavioral deficits but could have broader applications for anxiety.